The building blocks of multi-targeting RNA medicines
FORGE™
Platform
We are advancing a new generation of multi-targeting RNA medicines.
Our proprietary FORGE™ platform creates chemically optimized, fused oligonucleotides capable of modulating multiple validated targets in a single therapeutic construct—an approach designed to overcome the limitations of monogenic siRNA and ASO strategies.
Research & Development
Our platform is well-suited for complex, polygenic neurological diseases.
Our Team
Scientific Roadmap Built On Decades of Expertise
Claes Wahlestedt, MD, PhD
Chief Executive Officer
Jack Stahl, PhD
Chief Scientific Officer
Arthur Polk
Chief Financial and Business Officer
Olga Khorkova, PhD
Sr. Scientist / Fellow
Art Krieg, MD
Advisory Board
Mark Gurney, PhD MBA
Advisory Board
Jan Lundberg, MD PhD
Advisory Board
Zicai Liang, PhD
Advisory Board
Dave Butler, PhD
Advisory Board
Henrik Zetterberg, MD PhD
Advisory Board
Tinker's founders were awarded the first place prize at the 2024 Eli Lilly and Company Genetic Medicine Grand Challenge for novel therapeutic strategy to treat brain disorders, including Alzheimer’s disease and Dravet syndrome.
